Ipamorelin: The Selective GH Secretagogue That Spares Cortisol

Ipamorelin Overview & Molecular Profile

MECHANISM OF ACTION

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist at the ghrelin receptor (GHSR-1a). First described by Raun et al. in 1998, it is distinguished from other GHRPs by releasing GH without meaningfully elevating cortisol, prolactin, or ACTH at therapeutic doses—a selectivity profile unique among its class. Human data is limited to two PK/PD studies and a discontinued Phase II trial; the majority of evidence derives from rodent models.

Mechanism of Action: Hormonal Signaling & Receptor Binding

MOLECULAR STRUCTURE

Ipamorelin acts as an agonist at the ghrelin receptor (GHSR-1a) in the pituitary gland, stimulating the release of growth hormone through activation of specific signaling pathways. It mimics the action of the natural hormone ghrelin but with higher selectivity. The peptide stimulates GH release in a dose-dependent manner while maintaining the natural pulsatile pattern of GH secretion. Importantly, it does not significantly stimulate ACTH, cortisol, or prolactin release at physiological doses.

Selective Somatotroph Activation: The Clean GH Release Profile

Ipamorelin's pharmacokinetic profile reflects its design as a selective growth hormone secretagogue — achieving rapid, pulsatile GH release without the off-target hormonal effects that limit other GHRPs. Its short half-life is a feature, not a limitation, preserving the physiologic pulsatility of GH secretion.

The Selectivity Advantage: What Ipamorelin Does NOT Release

Ipamorelin's defining pharmacological feature is not what it stimulates but what it does not — a selectivity profile that distinguishes it from earlier growth hormone secretagogues. • Unlike GHRP-6 and GHRP-2, ipamorelin does not elevate plasma cortisol or ACTH at growth hormone-releasing doses. This avoids the catabolic and immunosuppressive effects of cortisol elevation. • No significant prolactin elevation occurs, eliminating the gynecomastia concerns associated with GHRP-2 at higher doses. • No ghrelin-mimetic appetite stimulation — unlike GHRP-6, which produces intense hunger within minutes of injection through direct ghrelin receptor activation in the hypothalamic arcuate nucleus.

Growth Hormone Release

Research demonstrates significant, dose-dependent increases in growth hormone levels following Ipamorelin administration, with peak GH concentrations occurring approximately 30-40 minutes post-injection. Studies consistently show that Ipamorelin maintains the natural pulsatile pattern of GH secretion rather than causing unnatural sustained elevation, which is considered beneficial for maintaining normal feedback regulation. While Ipamorelin's human data is limited (primarily PK/PD studies and a discontinued Phase II for postoperative ileus), the dose-dependent acute stimulation aligns with 3-10 fold increases in peak GH, with effects lasting approximately 2-3 hours per administration. The peptide has been studied for optimization of natural GH production patterns, though it has not been extensively studied for age-related hormone decline or adult growth hormone deficiency in clinical trials.

Selective GH Stimulation

One of Ipamorelin's most significant research advantages is its remarkable selectivity for growth hormone release without substantial effects on other pituitary hormones or stress hormones. Clinical studies demonstrate minimal impact on cortisol levels (unlike GHRP-6 and GHRP-2), negligible prolactin elevation, and no significant effects on FSH, LH, TSH, or ACTH at therapeutic dosages. This selectivity profile makes Ipamorelin invaluable for research requiring isolated study of GH pathway effects without confounding hormonal variables. The peptide's clean hormonal profile has made it the preferred GHRP for many endocrinology research applications studying GH deficiency, aging, and metabolic regulation.

Research Protocol Doses Reported in Published Literature

Research Disclaimer: Doses reported below are from published preclinical research protocols. Ipamorelin is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation. All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.

Safety & Tolerability

Ipamorelin's defining tolerability feature is selectivity: in its foundational pharmacology it stimulated growth-hormone release without meaningfully raising cortisol, prolactin, or ACTH, and without the appetite stimulation seen with other growth-hormone-releasing peptides — avoiding several of their characteristic side effects. Published human exposure is limited to pharmacokinetic/pharmacodynamic study and a completed Phase II trial; long-term human safety is not established. Human data: Human data comprises pharmacokinetic/pharmacodynamic study in volunteers and a completed Phase II trial for postoperative ileus (NCT00672074); ipamorelin's development for that indication was subsequently discontinued without approval, and no efficacy trials for growth-hormone deficiency, body composition, or anti-aging have been published. Long-term safety is uncharacterized. Regulatory status: Not approved for human use by any regulatory agency; available only as a research compound. Ipamorelin stimulated GH release without significantly increasing cortisol, prolactin, or ACTH at GH-releasing doses, and without the appetite stimulation of GHRP-6 — a selectivity profile that avoids several side effects associated with earlier growth-hormone-releasing peptides. Animal Ipamorelin stimulated GH release without significantly increasing cortisol, prolactin, or ACTH at GH-releasing doses, and without the appetite stimulation of GHRP-6 — a selectivity profile that avoids several side effects associated with earlier growth-hormone-releasing peptides. Ipamorelin advanced to a completed Phase II clinical trial for postoperative ileus (NCT00672074); its clinical development for that indication was later discontinued without regulatory approval. Human trial Ipamorelin advanced to a completed Phase II clinical trial for postoperative ileus (NCT00672074); its clinical development for that indication was later discontinued without regulatory approval.

Key Findings at a Glance

• Ipamorelin is called the first truly selective growth hormone secretagogue because it stimulates GH release without measurably raising cortisol, prolactin, or ACTH at therapeutic doses. • Unlike most GHRPs, Ipamorelin preserves the natural pulsatile rhythm of growth hormone release rather than forcing a continuous elevation, maintaining normal feedback regulation. • Ipamorelin has only a handful of human studies, primarily pharmacokinetic trials and a discontinued Phase II for postoperative ileus, making its widespread popularity largely based on animal data. • In glucocorticoid-treated rats mimicking osteoporosis, Ipamorelin counteracted steroid-induced bone loss by enhancing bone formation without changing bone mineral density markers.

Body Composition Effects

Research in animal models and preliminary human studies indicates Ipamorelin may influence body composition through GH-mediated pathways including enhanced lipolysis (fat breakdown), increased lean body mass, and improved fat-free mass to fat mass ratios. Studies have documented potential effects on visceral adipose tissue (belly fat), subcutaneous fat distribution, and skeletal muscle protein synthesis. The peptide has been investigated for applications in obesity research, sarcopenia (age-related muscle loss) studies, and metabolic syndrome investigations. Long-term administration studies in animals suggest sustained improvements in body composition metrics without significant adverse effects.

Bone Density Research

Studies suggest Ipamorelin may positively influence bone metabolism through mechanisms involving growth hormone and IGF-1 elevation,. While GH and IGF-1 positively influence bone metabolism, the direct effect of Ipamorelin on bones is less studied. Research in animal models has documented increased longitudinal bone growth in young subjects and increased bone mineral content (BMC) due to increased volume of bone, though bone mineral density itself remained unchanged. Note: No significant changes in bone turnover markers (osteocalcin and bone-specific alkaline phosphatase) were observed in studies,. The peptide was studied in an osteoporosis-mimicking model (glucocorticoid-induced bone loss in adult rats), where it enhanced bone formation. Studies show Ipamorelin causes pulsatile GH release (not sustained elevation), indicating it may preserve normal feedback regulation while potentially supporting bone remodeling processes.

Sleep and Recovery Research

The relationship between growth hormone secretion and sleep quality is well-established in endocrinology research, as natural GH release peaks during slow-wave (deep) sleep. Since Ipamorelin stimulates pulsatile GH release that mimics natural patterns, researchers have hypothesized potential benefits for sleep architecture. However, direct studies specifically evaluating Ipamorelin's effects on sleep quality metrics are limited. Any observed sleep-related effects would theoretically be mediated through GH pathway activation rather than direct CNS effects. Further research is needed to establish whether Ipamorelin administration influences sleep architecture, recovery processes, or subjective sleep quality in controlled settings.

Common Pairings

Ipamorelin is most often stacked with CJC-1295 (DAC). Pairing compounds that act through complementary pathways can broaden the effect without simply doubling one mechanism. Introduce a stack one compound at a time so you can attribute any change, and keep the total load conservative.

Stacking Principles

As a rule, more compounds is not better. Each addition adds cost, injection burden, and another variable to untangle if something feels off. Ask REGEN AI to sanity-check any stack against your goals and bloodwork before you start.

Rapid Absorption and GH Pulse Kinetics

Following subcutaneous administration, ipamorelin produces a discrete GH pulse that mimics the amplitude and duration of endogenous GH secretory episodes. • Subcutaneous Tmax is 15-30 minutes, with peak plasma ipamorelin concentrations followed by a terminal elimination half-life of approximately 2 hours. • GH release begins within 10 minutes of administration, peaks at 30-40 minutes, and returns to baseline by approximately 3 hours — producing a single, clean GH pulse per dose. • No accumulation occurs with repeated dosing. Each injection produces an independent GH secretory episode, preserving the pulsatile pattern that maintains GH receptor sensitivity.